EGFR and non-small cell lung carcinoma: Longer survival rates were detected in patients with exon 19 deletions treated with TKIs (Cote et al., 2011), while short progression free survival has been exhibited in NSCLC patient with T790M mutation received EGFR-TKI treatment (Shi et al., 2015).